CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 8,060,300 shares, an increase of 72.7% from the May 15th total of 4,666,400 shares. Based on an average daily trading volume, of 10,249,200 shares, the days-to-cover ratio […]
VANCOUVER, Washington, May 28, 2024 CytoDyn Inc. , a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that.
VANCOUVER, Washington, May 16, 2024 Dear Shareholders, I write today to provide an update on CytoDyn Inc. , as we approach the end of our 2024 fiscal year , and to sincerely thank you for.
Societal CDMO (NASDAQ:SCTL – Get Free Report) and CytoDyn (OTCMKTS:CYDY – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings. Institutional & Insider Ownership 87.2% of Societal CDMO […]